Sounds like an interesting collaboration ..... and some on here claimed the roadshows would be a big pile of (and I quote) "nothing new" .... looks like that theory is out the window ... lol
GLTAH
https://renovorx.com/
Standard of Care Pancreatic Cancer Treatment May be Ineffective for Treating Tumors and is Often Accompanied by Debilitating Side Effects
The Phase III TIGeR-PaC clinical trial is a randomized multi-center study using RenovoRx’s innovative therapy platform, RenovoTAMP® (RenovoRx Trans-arterial Micro-perfusion), to evaluate RenovoRx’s first product candidate, RenovoGem™, to treat locally advanced pancreatic cancer (LAPC) through the intra-arterial delivery of gemcitabine (an FDA-approved chemotherapy).
The goal of the study has a primary endpoint of overall survival and several secondary endpoints, including quality of life. TIGeR-PaC is currently enrolling locally advanced, unresectable LAPC patients.
Ann: Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration, page-19
-
- There are more pages in this discussion • 150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |